52 Week Range
As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
Feb 6 (Reuters) - Recipharm AB (publ) <RECIb.ST>::RECIPHARM ANNOUNCES THAT CONSORT MEDICAL APPLIES FOR DELISTING.RECIPHARM - CONSORT TO APPLY TO UK LISTING AUTHORITY AND LONDON STOCK EXCHANGE REQUESTING CANCELLATION OF LISTING OF CONSORT SHARES.ANY REMAINING CONSORT SHAREHOLDERS WILL BECOME MINORITY SHAREHOLDERS IN A PRIVATELY CONTROLLED LIMITED COMPANY.
Jan 29 (Reuters) - Recipharm AB <RECIb.ST>: :CONFIRMS THAT IT WILL NOT EXTEND ACCEPTANCE DEADLINE BEYOND FEB 4 FOR CONSORT MEDICAL OFFER.CONFIRMS THAT OFFER PRICE OF 1,010 PENCE PER CONSORT MEDICAL SHARE IS FINAL AND WILL NOT BE INCREASED.GOT WRITTEN NOTICE FROM IRISH COMPETITION AND CONSUMER PROTECTION COMMISSION THAT CONSORT DEAL MAY BE PUT INTO EFFECT.
Company corrects number of Consort shares and related holding.:RECIPHARM ACQUIRES SHARES IN CONSORT MEDICAL.ACQUIRED 4,815,000 CONSORT SHARES, 9.8% OF SHARE CAPITAL OF CONSORT AND FURTHER 185,000 CONSORT SHARES, REPRESENTING 0.4%.
Jan 24 (Reuters) - Consort Medical PLC <CSRT.L>::RECIPHARM FURTHER EXTENDS THE ACCEPTANCE PERIOD FOR THE OFFER TO ACQUIRE CONSORT MEDICAL AND UPDATES ON LEVEL OF ACCEPTANCE.OFFER IS BEING EXTENDED AND WILL REMAIN OPEN FOR ACCEPTANCES UNTIL 4 FEBRUARY 2020.
Jan 14 (Reuters) - Recipharm AB <RECIb.ST>::RECIPHARM RECEIVES COMPETITION CLEARANCE FROM GERMAN COMPETITION AUTHORITIES FOR THE OFFER TO ACQUIRE CONSORT MEDICAL.COMPLETION OF OFFER REMAINS SUBJECT TO OTHER OUTSTANDING CONDITIONS, SUCH AS IRISH ANTITRUST CONDITION AND ACCEPTANCE CONDITION, AS SET OUT IN OFFER DOCUMENT.
Jan 10 (Reuters) - Recipharm AB <RECIb.ST>::RECIPHARM EXTENDS THE ACCEPTANCE PERIOD FOR THE OFFER TO ACQUIRE CONSORT MEDICAL AND UPDATES ON LEVEL OF ACCEPTANCE.OFFER, WHICH REMAINS SUBJECT TO TERMS AND CONDITIONS SET OUT IN OFFER DOCUMENT AND, IN RESPECT OF CONSORT SHARES IN CERTIFICATED FORM, FORM OF ACCEPTANCE, IS BEING EXTENDED AND WILL REMAIN OPEN FOR ACCEPTANCES UNTIL 1.00 P.M. (LONDON TIME) ON 23 JANUARY 2020.
Dec 3 (Reuters) - Consort Medical PLC <CSRT.L>::H1 GROUP REVENUE DECLINED BY 4.3% TO £146.0M (H1 FY2019: £152.5M).H1 EBIT BEFORE SPECIAL ITEMS DECREASED BY 49.5% TO £10.5M (H1 FY2019: £20.8M).BOARD HAS NOT DECLARED AN INTERIM DIVIDEND DUE TO TERMS OF RECIPHARM'S OFFER (H1 FY2019: 7.60P).BOARD'S EXPECTATIONS FOR FULL YEAR REMAIN UNCHANGED.GROUP IS SUBJECT TO A RECOMMENDED OFFER FROM RECIPHARM HOLDINGS LTD. BOARD REMAINS CONFIDENT OF CONSORT'S FUTURE PROSPECTS.
Nov 26 (Reuters) - Recipharm Ab (Publ) <RECIb.ST>::Larger institutional shareholders support Recipharm's cash offer for Consort Medical and subsequent rights issue.Certain of Recipharm's larger institutional shareholders, Första AP-fonden, Lannebo Fonder and Fjärde AP-fonden (holding 7.4%, 7.1% and 5.1% of the total number of shares in Recipharm, respectively, and together 19.6%), support the cash offer for Consort Medical.These investors have undertaken to fully support and vote in favour of a rights issue at a forthcoming general meeting of Recipharm and have also undertaken to subscribe for an amount corresponding to at least their respective pro rata share in a rights issue of SEK 2,000 million.As previously announced, Recipharm's largest shareholders, Thomas Eldered and Lars Backsell (who together hold 27.1% of the total number of shares in Recipharm), have already undertaken to vote in favour of the rights issue at the forthcoming general meeting of Recipharm and have also undertaken to subscribe for an amount corresponding to their respective pro rata share in a rights issue of SEK 2,000 million.Current shareholders in Recipharm, together holding 46.6% of the total number of shares and 82.3% of the votes in Recipharm, have undertaken to vote in favour of a rights issue at a forthcoming general meeting of Recipharm and have also undertaken to subscribe for their respective pro rata share in the rights issue..
Nov 18 (Reuters) - Recipharm Ab (Publ) <RECIb.ST>::RECIPHARM OFFERS TO ACQUIRE CONSORT MEDICAL TO BECOME A LEADING INHALATION COMPANY AND TOP FIVE GLOBAL CDMO PLAYER.BOARD OF CONSORT HAS CONFIRMED ITS UNANIMOUS INTENTION TO RECOMMEND A CASH OFFER FOR AN EQUITY VALUE OF GBP 505 MILLION.SHAREHOLDERS OF CONSORT WILL RECEIVE GBP 10.10 IN CASH PER SHARE, VALUING ENTIRE SHARE CAPITAL AT GBP 505 MILLION (SEK 6,284 MILLION) ON A FULLY DILUTED BASIS.IT IS INTENDED THAT ACQUISITION WILL BE IMPLEMENTED BY WAY OF A TAKEOVER OFFER UNDER UK COMPANIES ACT.COMBINED ENTITY WILL ENHANCE RECIPHARM'S SCALE AND PROFITABILITY WITH ANNUAL PRO FORMA REVENUE OF SEK 10,847 MILLION AND PRO FORMA EBITDA OF SEK 1,793 MILLION.CONSORT HAD ANNUAL PRO FORMA REVENUE OF GBP 292 MILLION (SEK 3,633 MILLION) AND PRO FORMA EBITDA OF GBP 47 MILLION.ESTIMATED SEK 125 MILLION IN ANNUAL COST SYNERGIES, REALISED WITHIN 18 MONTHS AFTER COMPLETION WITH POTENTIAL FOR ADDITIONAL COST AND REVENUE SYNERGIES.OFFER REPRESENTS A PREMIUM OF 39% TO CONSORT'S CLOSING SHARE PRICE ON 15 NOVEMBER 2019, LAST BUSINESS DAY BEFORE TODAY'S ANNOUNCEMENT.TRANSACTION IS EXPECTED TO CLOSE IN Q1 2020.OFFER IS FULLY FINANCED THROUGH BANK FACILITIES ARRANGED BY, AND MADE AVAILABLE BY, DANSKE BANK A/S AND DNB BANK ASA, SWEDEN BRANCH,.INTENDS TO CARRY OUT ONE OR SEVERAL SHARE ISSUES OF APPROXIMATELY SEK 2,500 MILLION IN TOTAL.SHARE ISSUES ARE EXPECTED TO BE RESOLVED AND COMPLETED DURING FIRST HALF OF 2020.
Nov 18 (Reuters) - Recipharm AB (publ) <RECIb.ST>::RECIPHARM AB CONSORT MEDICAL PLC - RECOMMENDED CASH OFFER.PROPOSED DEAL VALUES ENTIRE ISSUED & TO BE ISSUED SHARE CAPITAL OF CONSORT AT ABOUT £505 MILLION ON A FULLY DILUTED BASIS.PROPOSED DEAL VALUES IMPLIES AN ENTERPRISE VALUE OF £627 MILLION FOR CONSORT.CONSORT DIRECTORS CONSIDER TERMS OF PROPOSED ACQUISITION TO BE FAIR AND REASONABLE..CONSORT DIRECTORS INTEND TO RECOMMEND UNANIMOUSLY THAT CONSORT SHAREHOLDERS ACCEPT, OR PROCURE ACCEPTANCE OF, OFFER.PROPOSED ACQUISITION IS FINANCIALLY COMPELLING AND EXPECTED TO BE SIGNIFICANTLY ACCRETIVE TO RECIPHARM GROUP'S CASH EARNINGS PER SHARE.ESTIMATES THAT WITHIN 18 MONTHS AFTER COMPLETION, SEK 125 MILLION (APPROXIMATELY £10.1 MILLION) IN ANNUAL COST SYNERGIES WILL BE REALISED.RECIPHARM GROUP EXPECTS PROPOSED ACQUISITION TO CLOSE IN Q1 2020..
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.